Takeda is offering about $5 billion to purchase Abbott’s stake of their U.S. joint venture. TAP has marketed two blockbusters – Prevacid and Lupron – but has recently stumbled.
Meanwhile, Takeda has been trying to grow its own organic presence in the U.S. Takeda will be getting TAP’s reps and its building north of Chicago.
